Literature DB >> 21273391

Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension.

H Chen1, T De Marco, E A Kobashigawa, P P Katz, V W Chang, P D Blanc.   

Abstract

Studies systematically comparing the performance of health-related quality-of-life (HRQoL) instruments in pulmonary arterial hypertension (PAH) are lacking. We sought to address this by comparing cardiac and respiratory-specific measures of HRQoL in PAH. We prospectively assessed HRQoL in 128 patients with catheterisation-confirmed PAH at baseline and at 6, 12 and post-24 month follow-up visits. Cardiac-specific HRQoL was assessed using the Minnesota Living with Heart Failure Questionnaire (LHFQ); respiratory-specific HRQoL was assessed using the Airways Questionnaire 20 (AQ20); and general health status was assessed using the 36-item Short Form physical component summary (SF-36 PCS). The LHFQ and AQ20 were highly intercorrelated. Both demonstrated strong internal consistency and converged with the SF-36 PCS. Both discriminated patients based on World Health Organization (WHO) functional class, 6-min walking distance (6MWD) and Borg dyspnoea index (BDI), with the exception of a potential floor effect associated with low 6MWD. The LHFQ was more responsive than the AQ20 to changes over time in WHO functional class, 6MWD and BDI. In multivariate analyses, the LHFQ and AQ20 were each longitudinal predictors of general health status, independent of functional class, 6MWD and BDI. In conclusion, both cardiac-specific and respiratory-specific measures appropriately assess HRQoL in most patients with PAH. Overall, the LHFQ demonstrates stronger performance characteristics than the AQ20.

Entities:  

Mesh:

Year:  2011        PMID: 21273391      PMCID: PMC3158810          DOI: 10.1183/09031936.00161410

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

1.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

2.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Authors:  M Kosinski; S Z Zhao; S Dedhiya; J T Osterhaus; J E Ware
Journal:  Arthritis Rheum       Date:  2000-07

3.  Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities.

Authors:  F Angst; A Aeschlimann; G Stucki
Journal:  Arthritis Rheum       Date:  2001-08

4.  Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

Authors:  Vallerie V McLaughlin; Alicia Shillington; Stuart Rich
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

5.  Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease.

Authors:  Berhanu Alemayehu; Ronald E Aubert; Richard A Feifer; Lester D Paul
Journal:  Value Health       Date:  2002 Sep-Oct       Impact factor: 5.725

6.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Authors:  Olivier Sitbon; Marc Humbert; Hilario Nunes; Florence Parent; Gilles Garcia; Philippe Hervé; Maurizio Rainisio; Gérald Simonneau
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

7.  Comparison of quality of life measures in heart failure.

Authors:  Susan J Bennett; Neil B Oldridge; George J Eckert; Jennifer L Embree; Sherry Browning; Nan Hou; Michelle Chui; Melissa Deer; Michael D Murray
Journal:  Nurs Res       Date:  2003 Jul-Aug       Impact factor: 2.381

8.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

9.  Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.

Authors:  T S Rector; J N Cohn
Journal:  Am Heart J       Date:  1992-10       Impact factor: 4.749

Review 10.  Quality of life measurement: bibliographic study of patient assessed health outcome measures.

Authors:  Andrew Garratt; Louise Schmidt; Anne Mackintosh; Ray Fitzpatrick
Journal:  BMJ       Date:  2002-06-15
View more
  16 in total

1.  Left ventricular subclinical dysfunction associated with myocardial deformation changes in obstructive sleep apnea patients estimated by real-time 3D speckle-tracking echocardiography.

Authors:  Dian Wang; Gen Shan Ma; Xiao Yan Wang; Qiang Qiang Lu; Yu Wang; Nai Feng Liu
Journal:  Sleep Breath       Date:  2015-05-24       Impact factor: 2.816

2.  An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.

Authors:  Ronald Oudiz; Manyoo Agarwal; Franz Rischard; Teresa De Marco
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 3.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

4.  Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Adaani Frost; Danielle Guffey; Charles G Minard; Mark L Entman
Journal:  Int J Cardiovasc Res       Date:  2015

5.  The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).

Authors:  Katarzyna Małaczynska-Rajpold; Anna Smukowska-Gorynia; Alice Heaney; Stephen P McKenna; Magdalena Janus; Aleksander Araszkiewicz; Stanislaw Jankiewicz; Sylwia Slawek-Szmyt; Iga Tomaszewska; Tatiana Mularek-Kubzdela
Journal:  Cardiol J       Date:  2018-10-19       Impact factor: 2.737

6.  Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension.

Authors:  Stephen C Mathai; Tomeka Suber; Rubina M Khair; Todd M Kolb; Rachel L Damico; Paul M Hassoun
Journal:  Ann Am Thorac Soc       Date:  2016-01

7.  Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.

Authors:  Nicholas A Kolaitis; Roham T Zamanian; Vinicio A de Jesus Perez; David B Badesch; Raymond L Benza; Charles D Burger; Murali M Chakinala; Jean M Elwing; Jeremy Feldman; Matthew R Lammi; Stephen C Mathai; John W McConnell; Kenneth W Presberg; Jeffrey C Robinson; Jeffrey Sager; Oksana A Shlobin; Marc A Simon; Steven M Kawut; David V Glidden; Jonathan P Singer; Teresa De Marco
Journal:  Ann Am Thorac Soc       Date:  2021-04

8.  The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).

Authors:  Katharina Cima; James Twiss; Rudolf Speich; Stephen P McKenna; Ekkehard Grünig; Christian M Kähler; Nicola Ehlken; Ursula Treder; Sigrid R Crawford; Lars C Huber; Silvia Ulrich
Journal:  Health Qual Life Outcomes       Date:  2012-09-13       Impact factor: 3.186

9.  Association Between Hemodynamic Profile, Physical Capacity and Quality of Life in Pulmonary Hypertension.

Authors:  Diego de Faria Magalhães Torres; Walter Araujo Zin; Agnaldo José Lopes; Patrícia dos Santos Vigário; Marcelo Iorio Garcia; Daniel Waetge; Marcelo Luiz da Silva Bandeira; Luiz Gustavo Pignataro Bessa; Fernando Silva Guimarães
Journal:  Arq Bras Cardiol       Date:  2015-02-27       Impact factor: 2.000

10.  Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Richard Channick; Dunbar Ivy; Brahm Goldstein
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.